Oncotelic Therapeutics Announces Opened Access To PDAOAI Evidence-Interrogation Platform

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data. The Company is also providing researchers access to a TGF-β literature corpus comprising all known publications for TGF-β- more than 125,000 PubMed abstracts- through a dedicated Discord research channel.